- Home
- EQS vs CMMB Comparison
EQS vs CMMB Comparison
Compare EQS & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQS
- CMMB
- Stock Information
- Founded
- EQS 1991
- CMMB 2004
- Country
- EQS United States
- CMMB Israel
- Employees
- EQS N/A
- CMMB N/A
- Industry
- EQS Finance Companies
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- EQS Finance
- CMMB Health Care
- Exchange
- EQS Nasdaq
- CMMB Nasdaq
- Market Cap
- EQS 20.1M
- CMMB 22.0M
- IPO Year
- EQS N/A
- CMMB N/A
- Fundamental
- Price
- EQS $1.88
- CMMB $0.92
- Analyst Decision
- EQS
- CMMB Strong Buy
- Analyst Count
- EQS 0
- CMMB 2
- Target Price
- EQS N/A
- CMMB $8.50
- AVG Volume (30 Days)
- EQS 52.3K
- CMMB 121.0K
- Earning Date
- EQS 01-01-0001
- CMMB 08-14-2025
- Dividend Yield
- EQS N/A
- CMMB N/A
- EPS Growth
- EQS N/A
- CMMB N/A
- EPS
- EQS N/A
- CMMB N/A
- Revenue
- EQS $1,329,000.00
- CMMB N/A
- Revenue This Year
- EQS N/A
- CMMB N/A
- Revenue Next Year
- EQS N/A
- CMMB N/A
- P/E Ratio
- EQS N/A
- CMMB N/A
- Revenue Growth
- EQS 152.66
- CMMB N/A
- 52 Week Low
- EQS $0.74
- CMMB $0.87
- 52 Week High
- EQS $2.11
- CMMB $2.55
- Technical
- Relative Strength Index (RSI)
- EQS 87.93
- CMMB 23.49
- Support Level
- EQS $1.35
- CMMB $0.91
- Resistance Level
- EQS $1.83
- CMMB $0.97
- Average True Range (ATR)
- EQS 0.12
- CMMB 0.06
- MACD
- EQS 0.02
- CMMB -0.01
- Stochastic Oscillator
- EQS 57.89
- CMMB 14.63
About EQS Equus Total Return Inc.
Equus Total Return Inc is a United States-based closed-end management investment company. It invests mainly in companies pursuing growth either through acquisition or organically, leveraged buyouts, management buyouts, and recapitalizations of existing businesses or special situations, and achieves capital appreciation by making investments in equity and equity-oriented securities issued by privately-owned companies or smaller public companies in transactions.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.